CTS-Clinical and Translational Science

Article	Citations
Gene polymorphism and prediction of toxicity to platinum‐based chemotherapy in patients with gynecologic cancer	173
Issue Information	100
Generalizability in real‐world trials	90
Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications	89
Intradermal substance P as a challenge agent in healthy individuals	71
ST2 and CSF‐1 as potential druggable targets of inflammatory bowel diseases: Results from two‐sample Mendelian randomization study	69
Pharmacogenomic landscape of Indian population using whole genomes	64
A Patient Centric Model for Vaso‐Occlusive Crises in Sickle Cell Disease—Outcomes of a Consensus Exercise Conducted Across Patients and Experts	56
Risk factors for the development of sepsis in patients with cirrhosis in intensive care units	53
Evidence of depot‐specific regulation of all‐trans‐retinoic acid biosynthesis in human adipose tissue	45
The impact of skin color and tone on histamine iontophoresis and Doppler flowmetry measurements as a pharmacodynamic biomarker	44
Nontraditional Factors Influencing Cardiovascular Disease Risk: Correlation Among Framingham Risk Score, Body Composition Index, and Sleep‐Breathing Monitoring Index	41
CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin	41
Japanese Phase 1 Study for Global Development of Anti‐TL1A Antibody PF‐06480605: A Randomized, Placebo‐Controlled, Single‐Ascending Dose Study	40
Lexicon for blood‐based early detection and screening: BLOODPAC consensus document	39
A comprehensive Thai pharmacogenomics database (TPGxD‐1): Phenotype prediction and variants identification in 942 whole‐genome sequencing data	38
Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community	36
Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection	33
Patient, industry, and regulatory perspective on antibody‐drug conjugates dose optimization	33
Developing a clinical research infrastructure embedded in an academic medicine center that equitably supports future clinician scientists	32
Using partition analysis as a facile method to derive net clearances	32
Expanding regulatory science: Regulatory complementarity and reliance	31
Issue Information	31
First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome	31
From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry	29

	29
First, Do No Harm: Addressing AI's Challenges With Out‐of‐Distribution Data in Medicine	28
Bridging Implementation Gaps in Digital Health: A Translational Research Imperative for Equitable Healthcare Innovation	28
Efficacy and safety of tofacitinib in rheumatoid arthritis: Nine years of real‐world data	27
Risk Factors Analysis of Cutaneous Adverse Drug Reactions Caused by Targeted Therapy and Immunotherapy Drugs for Oncology and Establishment of a Prediction Model	26
Recommended Clinical Context and Patient Context Data Elements for Liquid Biopsy Data Submitted to Data Repositories and Data Commons	25
Phase 1 Study Evaluating the Pharmacokinetics, Dose Proportionality, Bioavailability, and Tolerability of Subcutaneous Levothyroxine Sodium (XP‐8121)	25
Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants	24
Prevalence of actionable pharmacogenetic variants and high‐risk drug prescriptions: A Swiss hospital‐based cohort study	24
Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry – Informing optimal antiplatelet strategies	24
Concentration–Response Analysis of the Combination of Pyronaridine and Piperaquine on Corrected QT Interval From a Randomized, Double‐Blind, Placebo‐Controlled Study in Healthy Adults of Af	24
Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma	24
Human radiolabeled mass balance studies supporting the FDA approval of new drugs	22
Pharmacokinetics and Safety of Pelacarsen, a GalNAc 3 ‐Conjugated Antise	22
Radiolabelled Cyclodextrins for the Positron Emission Tomography Imaging of Breast Cancer: Preclinical Perspectives	22
Utilization of Machine Learning Approaches for Drug Clearance Prediction and Population Pharmacokinetic Covariate Analysis	22
Exploring the discrepancies between clinical trials and real‐world data: A small‐cell lung cancer study	21
Feasibility study for a fully decentralized clinical trial in participants with functional constipation symptoms	21
Gossypol improves myocardial dysfunction caused by sepsis by regulating histone acetylation	21
Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling Authority	21
First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor	21
Real‐world evidence to support regulatory submissions: A landscape review and assessment of use cases	21
Comprehensive analysis of clinical and biological features in Parkinson's disease associated with the LRRK2 G2019S mutation: Data from the PPMI study	21
Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants	20
Emapalumab in Patients With Macrophage Activation Syndrome Associated With Still's Disease: A Population Pharmacokinetic/Pharmacodynamic Analysis	20
Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3‐internal‐tandem‐duplication‐positive acute myeloid leukemia	20
Parkinson's disease: Still waiting for a cure	19
Hesitant adopters: An examination of hesitancy among adults in Arkansas who have taken the COVID‐19 vaccine	19
Real‐world evidence in the cloud: Tutorial on developing an end‐to‐end data and analytics pipeline using Amazon Web Services resources	19
Issue Information	19
Use cases of registry‐based randomized controlled trials—A review of the registries' contributions and constraints	19
Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study	19
Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors	19
Real‐world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community‐based cancer center	18
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC‐0214 in healthy volunteers	18
Effect of Whole‐Brain Radiotherapy Dose on the Occurrence of Otitis Media and Mastoiditis in Patients With Lung Cancer With Brain Metastasis	18
Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science	18
Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact	18
Effect of Selective Serotonin Reuptake Inhibitors on Coagulation: Fact or Fiction?	18
Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma Using Miriplatin Without the Need for Hydration	18
Pediatric CYP2D6 metabolizer status and post‐tonsillectomy nausea and vomiting after ondansetron	18
Comparing machine learning and deep learning models to predict cognition progression in Parkinson's disease	18
Associations of HLA genetic variants with carbamazepine‐induced cutaneous adverse drug reactions: An updated meta‐analysis	17
Cardiovascular risk of urate‐lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan	17
Assessment of QT Interval Prolongation Using Concentration– QT Modeling for Iptacopan, an Oral Com	17
The Role of Candidate Polymorphisms in Drug Transporter Genes on High‐Dose Methotrexate in the Consolidation Phase of the AIEOP‐BFM ALL 2009 Protocol	17
Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A /P‐gp Modulators	17
A Tutorial and Use Case Example of the eXtreme Gradient Boosting (XGBoost) Artificial Intelligence Algorithm for Drug Development Applications	16
Issue Information	16
Lidocaine as an anti‐arrhythmic drug: Are there any indications left?	16

	16
Free heme and hemopexin in acute kidney injury after cardiopulmonary bypass and transient renal ischemia	15
Academia and industry agreement on a feasibility tool for first‐time‐in‐human clinical trial units	15
Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma	15
Pharmacokinetic evaluation of radiolabeled intraocular anti‐CLEC14a antibody in preclinical animal species and application in humans	15
Issue Information	15
	15
Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach	15
Issue Information	15
Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis	15
CYP2C8*3 and *4 define CYP2C8 phenotype: An approach with the substrate cinitapride	15
Model‐informed precision dosing of teicoplanin for the rapid achievement of the target area under the concentration‐time curve: A simulation study	15
Issue Information	15
Prediction of molecular phenotypes for novel SCN1A variants from a Turkish genetic epilepsy syndromes cohort and report of two new patients with recessive Dravet syndrome	14
A Survey Study of Roadblocks in Translational Science	14
Issue Information	14
Insights From a User Experience‐Focused Virtual Study on the Feasibility and Challenges of Decentralized Clinical Trials	14
Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta‐analysis	14
Association between statin use and dry eye disease in patients with hyperlipidemia: A population‐based retrospective cohort study	14
Issue Information	14
Penetration of linezolid and tedizolid in cerebrospinal fluid of mouse and impact of blood–brain barrier disruption	14
Predicted expression of genes involved in the thiopurine metabolic pathway and azathioprine discontinuation due to myelotoxicity	14
Engaging student opinions on vaccine development innovation: Experiences from a “Shark Tank” project	14
What motivates people with type 2 diabetes mellitus to participate in clinical trials from home?	14
A Multicenter Randomized Controlled Study on Pharmacokinetic‐Guided Vancomycin Use in Children With Severe Infections	14
Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase‐4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas	14
A First‐In‐Human Phase 1 Study to Evaluate the Safety and Tolerability of LEM‐S401, a Novel siRNA‐DegradaBALL Drug Targeting CTGF in Healthy Adul	14
The “One‐Step” approach for QT analysis increases the sensitivity of nonclinical QTc analysis	14
Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open‐label, multiple‐dose study	13
MicroRNA sequencing in patients with coronary artery disease – considerations for use as biomarker for thrombotic risk	13
Effect of carrot intake on glucose tolerance, microbiota, and gene expression in a type 2 diabetes mouse model	13
Response to “DPYD genotyping panels: Impact of population diversity”	13
Machine learning framework to predict pharmacokinetic profile of small molecule drugs based on chemical structure	13
	13
Prediction of Cisplatin‐Induced Acute Kidney Injury Using an Interpretable Machine Learning Model and Electronic Medical Record Information	13
A Patient‐Derived 3D Cyst Model of Polycystic Kidney Disease That Mimics Disease Development and Responds to Repurposing Candidates	13
Ascites affects the benefit of carvedilol on patients with liver cirrhosis and esophageal and gastric varices	13
Critical Roles for Modeling and Simulation and Real‐World Evidence to Inform Challenges in Clinical Trial Diversity Planning	13
High intrapatient variability of tacrolimus exposure associated with poorer outcomes in liver transplantation	13
Artificial intelligence in rare disease diagnosis and treatment	13
Association between aortic calcification and cytokine levels in patients with peripheral artery disease	13
Proposing a framework to quantify the potential impact of pharmacokinetic drug–drug interactions caused by a new drug candidate by using real world data about the target patient population	13
Physiologically based absorption modeling to predict the bioequivalence of two apixaban formulations	13
A drug‐disease model for predicting survival in an Ebola outbreak	13
Integrating real‐world data and machine learning: A framework to assess covariate importance in real‐world use of alternative intravenous dosing regimens for atezolizumab	13
Dupilumab: Mechanism of action, clinical, and translational science	13
PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies	13
Lay understandings of drug‐gene interactions: The right medication, the right dose, at the right time, but what are the right words?	12
Optimizing expert and patient input in pediatric trial design: Lessons learned and recommendations from a collaboration between conect4children and European Patient‐CEntric ClinicAl TRial PLatforms	12
Leveraging patient‐centric sampling for clinical drug development and decentralized clinical trials: Promise to reality	12
Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants	12
Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long‐acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double‐blind, p	12
Updated DPYDHapB3 haplotype structure and implications for pharmacogenomic testing	12
Preclinical assessment of drug–drug interaction of fb‐PMT, a novel anti‐cancer thyrointegrin αvβ3 antagonist	12
Evaluation of potential drug–drug interactions with medical cannabis	12
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT‐787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial	12
A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects	12
Anticoagulant therapy in COVID‐19: A narrative review	12
Safety, pharmacokinetics, and pharmacodynamics of ART‐648, a PDE4 inhibitor in healthy subjects: A randomized, placebo‐controlled phase I study	12
Application of a patient‐centered reverse translational systems‐based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors	12
Comparison of glutaminase and cancer antigen 125 for distinguishing benign and malignant ovarian tumors	12
An overview of drug‐induced sodium channel blockade and changes in cardiac conduction: Implications for drug safety	12
Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase	12
Issue Information	12
Feasibility of preemptive pharmacogenetic testing and improvement of medication treatment satisfaction among medically underserved patients	12
Application of Machine Learning for Predicting Progression‐Free and Overall Survival in Patients With Renal Cell Carcinoma	12
Generic substitution of amlodipine is not associated with increased risk of mortality or adverse cardiovascular events: An observational cohort study	11
Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)	11
	11
Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose‐escalation phase I study	11
A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens	11
Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy	11
Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro	11
Postmarket safety communications on drugs approved in Japan: A 25‐year analysis	11
Association of Vancomycin Plus Piperacillin‐Tazobactam With Acute Kidney Injury: Differentiating Pseudo‐Injury From True Nephrotoxicity	11
An exploratory machine learning approach to identify placebo responders in pharmacological binge eating disorder trials	11
	11
Issue Information	11
Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro	11
No drug–drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants	11

Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole	11
Potential biomarkers for fatal outcome prognosis in a cohort of hospitalized COVID‐19 patients with pre‐existing comorbidities	11
Non‐synonymous alterations in AKR7A3 and ABCA6 correlate with bleeding in aged patients treated with rivaroxaban	11
Association between serum albumin to serum creatinine ratio and mortality risk in patients with heart failure	11
Considerations for addressing anti‐vaccination campaigns: How did we get here and what can we do about it?	11
Subtyping treatment response of tirofiban in acute ischemic stroke based on neuroimaging features	11
Cardiac sodium channel inhibition by lamotrigine: In vitro characterization and clinical implications	10
Regulation of exosomes as biologic medicines: Regulatory challenges faced in exosome development and manufacturing processes	10
	10
A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens	10
Issue Information	10
Age‐related off‐label drug prescribing in pediatric patients in South Korea and consistency of labeling compared to the United States, Europe, and Japan	10
Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC	10
Atogepant: Mechanism of action, clinical and translational science	10
High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID‐19 Treatment	10
Opportunities and challenges of 5G network technology toward precision medicine	10
Informing Implementation Strategies for Pharmacogenomics in Cancer: Development of Survey Tools for Healthcare Professionals and Consumers	10
Standardization, Education, and Resourcing: The Way Forward for Implementing Polygenic Risk Scores in Hereditary Breast and Ovarian Cancer	10
Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations	10
Remimazolam versus propofol in combination with esketamine for surgical abortion: A double‐blind randomized controlled trial	10
Expression of Concern: Liu, X., Zhong, L., Li, P., & Zhao, P. MicroRNA‐100 Enhances Autophagy and Suppresses Migration and Invasion of Renal Cell Carcinoma Cells via Disruption of NOX4‐Depe	10
Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?	10
Drug Interaction PBPK Modeling: Review of the Literature Exposes the Need for Increased Verification of Model Inputs and Outputs as Part of Credibility Assessment	10
Use of Biomarkers in Drug Development for Regulatory Purposes	10
Safety, Tolerability, and Pharmacokinetics of NIM‐1324 an Oral LANCL2 Agonist in a Randomized, Double‐Blind, Placebo‐Controlled Phase I Clinical Trial	9
Predicting Vancomycin Clearance in Neonates and Infants by Integrating Machine Learning and Metabolomics With Population Pharmacokinetics	9
Pharmacokinetics of Bocidelpar, ASP0367, in Renal and Hepatic Impairment: Results From Two Phase 1 Studies	9
Insights and lessons learned from a prospective clinical pharmacology study in allogeneic hematopoietic stem cell transplant during the COVID‐19 pandemic	9
How can real‐world evidence aid decision making during the life cycle of nonprescription medicines?	9
Surfing the T Wave: A Primer on ECG T Wave Morphologies Encountered in Clinical Trials and Impact on the QT Interval and Patient Safety	9
A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence	9
Corrigendum to: Integrating real‐world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women	9
Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review	9
	9
A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS‐CoV‐2(−)/(+) populations	9
Controlled oxygenated rewarming as novel end‐ischemic therapy for cold stored liver grafts. A randomized controlled trial	9
Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors	9
Proteomics Used in Identifying Novel Correlates of Disease in Pediatric Metabolic Dysfunction‐Associated Steatotic Liver Disease	9
Differential effects of metformin‐mediated BSEP repression on pravastatin and bile acid pharmacokinetics in humans: A randomized controlled trial	9
Decentralized Clinical Trials in the Era of Real‐World Evidence: A Statistical Perspective	9
Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double‐blind placebo‐controlled cross‐over study	9
Issue Information	9
First‐In‐Human, Randomized, Placebo‐Controlled, SAD and MAD Trial to Evaluate Safety, Tolerability, and PK/PD Modeling of Potravitug in Healthy Adults	9
Global harmonization of immediate‐release solid oral drug product bioequivalence recommendations and the impact on generic drug development	9
Large‐Scale Analysis of Age and Sex Effects on Corrected QT and JT Intervals: Insights From Hospital‐Based Controls and Moxifloxacin‐Treated Cases	9
Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions	9
Pharmacokinetics and Safety of Fixed‐Dose Versus Separate Enavogliflozin/Gemigliptin Combinations, and Food Effect on Enavogliflozin in Healthy Korean Subjects	9
Pharmacokinetics and Safety of Polaprezinc Granules Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions	8
Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data	8
	8
Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer	8
The Cardiac Sodium Channel Safety Profile of Cenobamate at Therapeutic Concentrations: In Vitro Analyses	8
Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole	8
Tutorial: Microbiome studies in drug metabolism	8
Integrating Sustainability Pillars Into Trial Design Decision‐Making: Results of an International Survey	8
Developing a mechanistic translational PK/PD model for a trifunctional NK cell engager to predict the first‐in‐human dose for acute myeloid leukemia	8
Pharmacogenomic variation and sedation outcomes during early intensive care unit admission: A pragmatic study	8
Biolink Model: A universal schema for knowledge graphs in clinical, biomedical, and translational science	8
Optimizing a therapy for opiate use disorders: Characterizing ondansetron pharmacokinetics in blood and brain	8
Pharmacokinetic comparison of subcutaneously administered CT‐P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants	8
Association of CYP2C19 genotypes with postoperative atrial fibrillation after coronary artery bypass surgery	8
Continuation Versus Discontinuation of Sodium‐Glucose Cotransporter‐2 Inhibitors and Cardiorenal Outcomes Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Cohort Study With	8
BLOODPAC: Collaborating to chart a path towards blood‐based screening for early cancer detection	8
Issue Information	8
Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study	8
Leveraging large observational studies to discover genetic determinants of drug concentrations: A proof‐of‐concept study	8
Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer	8
Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like re	8
Association between psychomotor function and ALDH2 genotype after consuming barley shochu: A randomized crossover trial	8
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled,	8
Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism	8
The expanding universe of NUTM1 fusions in pediatric cancer	8
	8
	8
Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers	8
Umbilical cord blood–derived exosomes from healthy term pregnancies protect against hyperoxia‐induced lung injury in mice	8
Rapid identification and phenotyping of nonalcoholic fatty liver disease patients using a machine‐based approach in diverse healthcare systems	8
Effect of enzalutamide on PK of P‐gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters	8
Translational researchers’ training and development needs, preferences, and barriers: A survey in a National Institute for Health Research Biomedical Research Centre in the United Kingdom	8
Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti‐ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies	8
Thai pharmacogenomics database −2 (TPGxD‐2) sequel to TPGxD‐1, analyzing genetic variants in 26 non‐VIPGx genes within the Thai population	8
Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients	8
Safety, Pharmacokinetics and Target Engagement of a Novel Brain Penetrant RIPK1 Inhibitor (SIR9900) in Healthy Adults and Elderly Participants	8
Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data	7
First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2	7
Rademikibart (CBP‐201), a next‐generation monoclonal antibody targeting human IL‐4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis	7
Screening and characterization of myositis‐related autoantibodies in COVID‐19 patients	7
Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stabl	7
A multi‐purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo‐controlled, single‐ascending dose study in adults	7
Randomized evaluation of the loss‐of‐function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics	7
Clinical Outcomes and Safety Profiles of Generic Versus Brand‐Name Clopidogrel in Patients Following Coronary Artery Stent Placement	7
Healthcare professionals' and consumers' knowledge, attitudes, perspectives, and education needs in oncology pharmacogenomics: A systematic review	7
Higher Education Influences Stroop Performance in Non‐Demented Older Adults: The Mediating Role of Resting‐State Brain Activity	7
Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study	7
Continuous versus intermittent infusion of human antithrombin III concentrate in the immediate postoperative period after liver transplantation	7